<code id='53F3B5A35A'></code><style id='53F3B5A35A'></style>
    • <acronym id='53F3B5A35A'></acronym>
      <center id='53F3B5A35A'><center id='53F3B5A35A'><tfoot id='53F3B5A35A'></tfoot></center><abbr id='53F3B5A35A'><dir id='53F3B5A35A'><tfoot id='53F3B5A35A'></tfoot><noframes id='53F3B5A35A'>

    • <optgroup id='53F3B5A35A'><strike id='53F3B5A35A'><sup id='53F3B5A35A'></sup></strike><code id='53F3B5A35A'></code></optgroup>
        1. <b id='53F3B5A35A'><label id='53F3B5A35A'><select id='53F3B5A35A'><dt id='53F3B5A35A'><span id='53F3B5A35A'></span></dt></select></label></b><u id='53F3B5A35A'></u>
          <i id='53F3B5A35A'><strike id='53F3B5A35A'><tt id='53F3B5A35A'><pre id='53F3B5A35A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:34
          Sammy Kimball for STAT

          Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

          advertisement

          For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Readout Newsletter: The latest on Moderna, Apellis, and Merck
          Readout Newsletter: The latest on Moderna, Apellis, and Merck

          JakubPorzycki/NurPhotoviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetou

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          David Ricks of Eli Lilly: best biopharma CEO of 2023

          HyacinthEmpinado/STATIt’sthattimeoftheyearagainwhenIrecognizetheBestBiopharmaCEOoftheyear.Thisyear’s